Baricitinib, JAK inhibitors and liver injury: a cause for concern in COVID-19?

Click to increase image sizeClick to decrease image size

Authors’ contributions

Emanuel Raschi conceived the letter and drafted the first version. All authors critically revised the letter and approved its final version.

Declaration of interest

E Raschi reports personal fees from Novartis, outside the submitted work. Other authors declare no conflict of interest relevant to the content and the preparation of this letter. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Additional information

Funding

This letter was not funded.